These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20477209)

  • 1. Recent advances in antituberculous drug development and novel drug targets.
    Tomioka H; Tatano Y; Yasumoto K; Shimizu T
    Expert Rev Respir Med; 2008 Aug; 2(4):455-71. PubMed ID: 20477209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of new antituberculous agents based on new drug targets and structure-activity relationship.
    Tomioka H
    Expert Opin Drug Discov; 2008 Jan; 3(1):21-49. PubMed ID: 23480138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities.
    Tomioka H
    Curr Pharm Des; 2006; 12(31):4047-70. PubMed ID: 17100611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospects for the development of new antituberculous drugs putting our hopes on new drug targets].
    Tomioka H
    Kekkaku; 2010 Nov; 85(11):815-22. PubMed ID: 21174739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing TB in the 21st century: existing and novel drug therapies.
    Guy ES; Mallampalli A
    Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future prospects of molecular epidemiology in tuberculosis].
    Matsumoto T; Iwamoto T
    Kekkaku; 2009 Dec; 84(12):783-4. PubMed ID: 20077862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility testing of levofloxacin and ofloxacin by microtiter plate Alamar blue against multidrug and non multidrug resistant Mycobacterium tuberculosis in Thailand.
    Pracharktam R; Angkananukool K; Vibhagool A
    J Med Assoc Thai; 2001 Sep; 84(9):1241-5. PubMed ID: 11800295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    Respir Med; 2009 Dec; 103(12):1777-90. PubMed ID: 19660927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
    Tomioka H; Tatano Y; Sano C; Shimizu T
    J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensively drug-resistant tuberculosis in sub-Saharan Africa: an emerging public-health concern.
    Jones KD; Hesketh T; Yudkin J
    Trans R Soc Trop Med Hyg; 2008 Mar; 102(3):219-24. PubMed ID: 18243260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant and extensively drug-resistant tuberculosis in the West. Europe and United States: epidemiology, surveillance, and control.
    Migliori GB; D'Arcy Richardson M; Sotgiu G; Lange C
    Clin Chest Med; 2009 Dec; 30(4):637-65, vii. PubMed ID: 19925959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships for a series of quinoline-based compounds active against replicating and nonreplicating Mycobacterium tuberculosis.
    Lilienkampf A; Mao J; Wan B; Wang Y; Franzblau SG; Kozikowski AP
    J Med Chem; 2009 Apr; 52(7):2109-18. PubMed ID: 19271749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide deformylase--a promising therapeutic target for tuberculosis and antibacterial drug discovery.
    Sharma A; Khuller GK; Sharma S
    Expert Opin Ther Targets; 2009 Jul; 13(7):753-65. PubMed ID: 19530983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development.
    Ma Z; Lienhardt C
    Clin Chest Med; 2009 Dec; 30(4):755-68, ix. PubMed ID: 19925965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis.
    Bapela NB; Lall N; Fourie PB; Franzblau SG; Van Rensburg CE
    Phytomedicine; 2006 Nov; 13(9-10):630-5. PubMed ID: 16987644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for MDR-TB (multi-drug resistant tuberculosis)--its feasibility].
    Tsuyuguchi I
    Kekkaku; 1999 Jun; 74(6):479-91. PubMed ID: 10423959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.